Evidence map›Paper›PMID 35340888›Full record

ReviewBreast cancer : basic and clinical research2022

Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer - A Systematic Review.

Matthew G Davey, Martin S Davey, Vinitha Richard, William Wyns, Osama Soliman, Nicola Miller, Aoife J Lowery, Michael J Kerin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast cancer : basic and clinical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Matthew G DaveyDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Galway, Ireland.ORCID https://orcid.org/0000-0002-9892-9920
Martin S DaveyDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Galway, Ireland.
Vinitha RichardDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Galway, Ireland.
William WynsPrecision Cardio-Oncology Research Enterprise (P-CORE), National University of Ireland, Galway, Galway, Ireland.
Osama SolimanPrecision Cardio-Oncology Research Enterprise (P-CORE), National University of Ireland, Galway, Galway, Ireland.ORCID https://orcid.org/0000-0003-0758-3539
Nicola MillerDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Galway, Ireland.
Aoife J LoweryDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Galway, Ireland.
Michael J KerinDiscipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Galway, Ireland.
Ollscoil na Gaillimhe – University of Galway · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Increased appreciation of the human epidermal growth factor receptor-2 (HER2/neu) signalling pathway has led to the development of targeted therapeutic agents used in conjunction with chemotherapy to improve outcomes for HER2 overexpressing (HER2+) breast cancer. For neoadjuvant therapy, response rates can be unpredictable - novel biomarkers predicting effectiveness are required to enhance oncological outcomes for these patients, and microRNA may prove effective. Our objective was to identify microRNA (miRNA) expression patterns predictive of response to neoadjuvant chemotherapy (NAC) and/or anti-HER2 targeted therapies in patients being treated for early-stage HER2+ breast cancer. Methods: A search was performed of the PUBMED, SCOPUS, Web of Science, and EMBASE in accordance to Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Results: Overall, 15 studies including 1335 patients were included. These studies highlighted an expression profile of 73 miRNA and their ability to predict tumour response to neoadjuvant therapies was correlated. Results from 11 studies were in relation to circulatory miRNA and 4 studies included data from tumour tissue. Overall, upregulation and downregulation of 41 miRNA and 29 miRNA, respectively, predicted differential response to neoadjuvant therapy. Expression levels of 3 miRNA (miR-21, miR-210, and miR-376c-3p) were inconclusive in predicting therapeutic response, while 'aberrant' expression of circulating miR-199a predicted pathological complete response (pCR) to NAC. Conclusions: This systematic review outlines expression patterns of a number of miRNA which correlate with response to NAC and/or anti-HER2 therapies. Future translational research evaluating predictive biomarkers of primary response to neoadjuvant therapy in HER2+ breast cancer may consider these results.

Indexed as

Breast cancermicroRNAnon-coding RNApathological complete responsepersonalised medicineprecision medicine

Identifiers

PMID35340888
PMCPMC8943461
OpenAlexW4220958512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.